A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments.
Following part one, which presented background to diabetic foot ulcers and the principles thought to explain hard-to-heal wounds, part two of this series reviews the efficacy and cost data indicating that certain wound treatments may be of benefit.
White
R
R
University of Worcester, UK. r.white@worc.ac.uk
McIntosh
C
C
D000287:Administration, Topical; D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use; D001458:Bandages / Q000191:economics / Q000600:supply & distribution; D000077214:Becaplermin; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use; D003094:Collagen / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017719:Diabetic Foot / Q000628:therapy*; D005060:Europe; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D054843:Negative-Pressure Wound Therapy; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D020574:Proto-Oncogene Proteins c-sis; D017592:Skin Care / Q000191:economics / Q000379:methods*; D016896:Treatment Outcome; D014945:Wound Healing
D043925:Angiogenesis Inducing Agents; C117898:Apligraf; D020099:Coated Materials, Biocompatible; D036341:Intercellular Signaling Peptides and Proteins; D010982:Platelet-Derived Growth Factor; D011480:Protease Inhibitors; D020574:Proto-Oncogene Proteins c-sis; C512800:TransCyte; D000077214:Becaplermin; D003094:Collagen